

[CLICK HERE](#)
Property Server for Lotus Domino

Intellectual Property Network
To Search & Research
[Home](#) | [Search](#) | [Order](#) | [Shopping Cart](#) | [Login](#) | [Site Map](#) | [Help](#)

WO9819679A1:

CYCLOPENTYLXANTHINE DERIVATIVES FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS

[View Images \(27 pages\)](#) | [View Cart](#) | [View INPADOC only](#)
[Add to cart: PDF \(-2570 KB\)](#) | [TIFF](#) | [Fax](#) | [File History](#) |
[More choices...](#)

Country: **WO** World Intellectual Property Organization (WIPO)

Kind: **A1** Publ.OF the Int.Appl. with Int.Search Report

Inventor(s): **McPHERSON, Margaret, Ann** , Wenvoe, Craig-y-Eos Road, Ogmores-by-Sea, Mid Glamorgan CF32 0PG, United Kingdom
DORMER, Robert, Leslie , Wenvoe, Craig-y-Eos Road, Ogmores-by-Sea, Mid Glamorgan CF32 0PG, United Kingdom
PEREIRA, Malcolm, Martin, Claude , 6 Longspears Avenue, Heath, Cardiff CF4 3NU, United Kingdom

Applicant(s): **UNIVERSITY OF WALES COLLEGE OF MEDICINE**, Heath Park, Cardiff CF4 4XN, United Kingdom
[News, Profiles, Stocks and More about this company](#)

Issued/Filed Dates: **May 14, 1998 / Nov. 5, 1997**

Application Number: **WO1997GB0003036**

IPC Class: **A61K 31/52;**

ECLA Code: **A61K31/52L5; C07D473/06;**

Priority Number(s): **Nov. 5, 1996 GB1996000229810**

Legal Status:  [Show legal status actions](#)

Designated Countries: **AU, CA, US**

Abstract: **The use of derivatives of theophylline for the preparation of**

medicaments suitable for the treatment of Cystic Fibrosis is described. In particular, the use of 8-cyclopentyl theophylline (CPT) is described for the preparation of medicaments for the treatment of cystic fibrosis. Such medicaments may be administered orally or directly to the lung, for example, in the form of an aerosol.
[[Show "fr" Abstract](#)]

Attorney, Agent, or
Firm:
Family:

NEWELL, William, Joseph;



[Show 7 known family members](#)

Other Abstract Info:

CHEMABS 129(02)019682C CAN129(02)019682C DERABS C98-286578
DERC98-286578

Foreign References:

(No patents reference this one)



[Nominate this
invention
for the Gallery...](#)

**Alternative
Searches**

 [Patent Number](#)

 [Boolean Text](#)

 [Advanced Text](#)

Browse

 [U.S. Class
by title](#)

 [U.S. Class
by number](#)

TDB
[IBM Technical
Disclosure Bulletin](#)

[Privacy](#) | [Legal](#) | [Gallery](#) | [IP Pages](#) | [Advertising](#) | [FAQ](#) | [Contact Us](#)

administration.

4. The use according to Claim 6 wherein the medicament
15 administered in an amount of 0.001 to 25 mg/kg body
per day.

5. The use according to Claim 1 or Claim 2 wherein
medicament is suitable for administering directly
lung.

20 6. The use according to Claim 5 wherein the medicament
is a pharmaceutically acceptable aerosol.

SUBSTITUTE SHEET (RULE 26)



19 / 27

OrderPatent




WO 98/19679

PCT/A

17


Claims

1. The use of a compound of formula (1),



wherein R¹ and R² are the same or different and
 5 represents an alkyl group having from 1 to 5 carbon
 provided that R¹ and R² are not both propyl groups,
 preparation of a medicament for the treatment of
 fibrosis.

2. The use according to Claim 1 of a compound of
 10 (1) wherein R¹ and R² are both methyl groups.
3. The use according to Claim 1 or Claim 2 where
 medicament is suitable for oral or parenteral



wherein R^1 and R^2 are the same or different and
represents an alkyl group having from 1 to 5 carbon atoms.

SUBSTITUTE SHEET (RULE 26)



20 / 27

OrderPatent



OrderPatent

WO 98/19679


PCT/

18

7. The use according to Claim 6 wherein the contains from 0.001 to 0.01% w/w of the compound of (1).


8. A compound of formula (1)

5



wherein R¹ and R² are the same or different a represents an alkyl group having from 1 to 5 carbon provided R¹ and R² are not both methyl groups or groups.

10 9. A pharmaceutical formulation comprising a compound of formula (1)





21 / 27

OrderPatent

WO 98/19679

PCT/

19

provided R^1 and R^2 are not both propyl groups, together with a pharmaceutically acceptable carrier therefor.


10. The formulation according to Claim 9 which is for oral administration.

5 11. The formulation according to Claim 9 which is for administration direct to the lung.

12. The formulation according to Claim 11 which is in the form of a pharmaceutically acceptable aerosol.

13. The formulation according to Claim 9 which is for parenteral administration.

14. A method of treating cystic fibrosis comprising administering a compound of formula (1)



where R^1 and R^2 are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms provided

15 R^1 and R^2 are the same or different and each represents

15 R and R' are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms provided R and R' are not both propyl groups.

15. The method of claim 14 wherein the compound of (1) is administered orally.

20 16. The method of claim 14 wherein the compound of (1) is administered intranasally.

17. The method of claim 14 wherein the compound of (1) is administered parenterally.

SUBSTITUTE SHEET (RULE 26)



21 / 27

OrderPatent